Lymphoma Clinical Trials in Salvador, Estado de Bahia

7 recruitingSalvador, Estado de Bahia, Brazil

Showing 17 of 7 trials

Recruiting
Phase 3

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

Follicular Lymphoma ( FL)
Regeneron Pharmaceuticals822 enrolled190 locationsNCT06091254
Recruiting
Phase 3

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Relapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Regeneron Pharmaceuticals470 enrolled168 locationsNCT06149286
Recruiting
Phase 3

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Lymphoma
Hoffmann-La Roche182 enrolled75 locationsNCT06084936
Recruiting
Phase 3

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B Cell Lymphoma
Genmab360 enrolled177 locationsNCT06508658
Recruiting
Phase 3

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma (B-NHL)
Regeneron Pharmaceuticals216 enrolled99 locationsNCT06230224
Recruiting

Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies

Diffuse Large B Cell LymphomaAcute Lymphoblastic LeukemiaFollicular Lymphoma
Novartis Pharmaceuticals200 enrolled7 locationsNCT05541341
Recruiting
Phase 1Phase 2

A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

Indolent B-Cell Non-Hodgkin Lymphoma
BioInvent International AB140 enrolled27 locationsNCT03571568